Summit Therapeutics’ mission is to resolve serious, unmet medical needs for the betterment of overall human health. Summit’s leadership is committed to making a significant positive difference in the quality and potential duration of life for oncology patients facing difficult diagnoses.

2 days ago · Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the...

2 days ago · MIAMI, February 24, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 ...

2 days ago · Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs).. Miami-based Summit holds the ...

2 days ago · Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors. Click to read why SMMT stock is a Strong Buy.

Dec 20, 2024 · Summit Therapeutics is running a pair of phase 3 clinical trials in the U.S. to support ivonescimab's approval in the country. The company is going after an important target:...

Sep 17, 2024 · Biotech investors have been buzzing with enthusiasm for Summit Therapeutics (NASDAQ: SMMT) and its lead candidate, ivonescimab. Recently announced results from a clinical trial with frontline...

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Sep 8, 2024 · Study results showed Summit’s drug cut the risk of lung cancer progression or death by half compared to Keytruda, a finding doctors described as impressive. Summit Therapeutics tested its drug ivonescimab against Keytruda in people with previously untreated lung cancer. Mohammed Haneefa Nizamudeen via Getty Images.